ELDN Eledon Pharmaceuticals Inc. Total Asset Value of Company
Eledon Pharmaceuticals (ELDN) focuses on establishing durable patents within the immunology sector, where the treatment of chronic pathologies guarantees steady demand. Market fluctuations in the share price reflect the dynamics of total assets, which currently stand at 135.50. However, the absence of current sales leaves the company dependent on external investment. The business is currently seeking a major partner to bring its developments to market.
Analytical breakdowns and data insights for company Eledon (ELDN)
- stock quotes and analyst forecast:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Eledon Pharmaceuticals|ELDN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Eledon Pharmaceuticals, Inc|ELDN - Company Aggregate Debts|Debts to Book Capitalization Eledon Pharmaceuticals, Inc|ELDN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Eledon Pharmaceuticals|Interim Coverage Ratio eledon.com
- net income and valuation multiples indicators:
Fundamental valuation:Eledon Pharmaceuticals
To assess long-term risks, it is critical for an investor to understand the actual scale of a company's resources. This indicator represents the sum of liabilities and equity, calculated inversely via return on assets (ROA) to eliminate reporting time lags. Analyzing this valuation of the company's financial assets allows for the tracking of fundamental base dynamics in real time. For Eledon Pharmaceuticals (ELDN), the growth of these metrics confirms the material base for the development of innovative antibodies in transplantology.
Key competitors
Total Business Assets ARGX|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|Savara Corp - Company Total Assets|Company Assets Rigel Corp|AnaptysBio, Inc. (ANAB) - Aggregate Company Assets|ATXS (astriatx.com) - Aggregate Company Assets|ENGN (enGene) - Company Total Assets|Company Assets RAPT Therapeutics Inc. RAPT|Company Total Assets JBIO|Aclaris Therapeutics, Inc - Total Business Assets|Aggregate Company Assets Kyverna Therapeutics KYTX|tizianalifesciences.com (TLSA) - Company Assets|CABA - Aggregate Company Assets|VTYX (Ventyx Biosciences Inc.) - Total Business Assets|THTX (Theratechnologies Inc) - Cumulative Company Assets|Avalo Therapeutics Inc - Aggregate Asset Value|Aggregate Company Assets Agenus|climbbio.com - Total Asset Value of Company|Company Total Assets ZURA|ATYR (aTyr Pharma Inc) - Aggregate Asset Value|Company Total Assets ADAG (Adagene Inc.)|Company Total Assets ImageneBio IMA|STTK - Aggregate Company Assets|Aggregate Asset Value EQ (Equillium, Inc.)|connectbiopharm.com (CNTB) - Aggregate Company Assets|Cumulative Company Assets Immunic|ATRA (Atara Biotherapeutics, Inc.) - Company Total Assets|Company Total Assets InflaRx GmbH|Company Total Assets XFOR|Cumulative Company Assets adicetbio.com ACET|Company Total Assets CELU (Celularity)|INmune Bio Inc (INMB) - Company Assets|BRNS: Cumulative Company Assets|KZR - Company Total Assets|SABS (SAB Biotherapeutics) - Cumulative Company Assets|AKTX: Aggregate Business Assets|ENLV (Enlivex Therapeutics Ltd) - Company Total Assets|Q32 Bio Corp (QTTB) - Company Total Asset Base|Company Total Assets GOVX|Cumulative Company Assets Edesa Biotech Corp EDSA|Company Total Assets IBIO (iBio, Inc.)|Company Total Assets Carisma Therapeutics Inc CARM|XTLB - Aggregate Company Assets|BOLT: Aggregate Company Assets|hcwbiologics.com (HCWB) - Aggregate Company Assets|APVO - Company Total Asset Base|AIM (AIM ImmunoTech Inc.) - Company Total Assets|Company Assets Aditxt Corp ADTX|Aggregate Company Assets GRI Bio (GRI)|Aggregate Company Assets XRTX (XORTX Therapeutics Inc)|Company Total Assets HIND (ReShape Lifesciences)|REVB: Total Business Assets|INDP - Aggregate Company Assets|SCNI (scinai.com) - Total Business Assets|calcimedica.com (CALI) - Aggregate Company Assets|Total Asset Value of Company AFMD (Affimed N.V.)|ALLK (Allakos Inc) - Company Total Assets|HOOK: Aggregate Asset Value|Company Total Assets IGMS|Company Total Assets iteostherapeutics.com (ITOS)|Aggregate Company Assets Ocean Biomedical OCEA|Aggregate Asset Value TCBP|THRD - Aggregate Company Assets